All In Biotech

Drug Trial Radar · NCT07333469

A Clinical Study of HX111 in Patients With Advanced Solid Tumor and Lymphoma

A Phase I/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of HX111 in Patients With Advanced Solid Tumor and Lymphoma

Last checked: Nov 19, 2026Latest source record: Jan 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

70

Planned (sponsor's estimate)

Start

Jan 19, 2026

Primary completion

Jan 19, 2028

Study completion Jan 19, 2030

Sponsor

Sponsor type
Industry
First posted
Jan 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will consist of a Phase I dose-escalation and Phase IIa dose-expansion component. Phase I dose-escalation phase will establish the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D),and evaluate the preliminary antitumor activity of HX111.

Conditions

  • Solid Tumor and Lymphoma

Interventions

  • HX111 for injectionDrug

    HX111, 0.5-2.5mg/kg, once every 3 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DLTsTime frame: 21 days

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.